Orakl Oncology Raises $34M to Expand AI-Powered Cancer Drug Prediction

November 12, 2026
Orakl Oncology Raises $34M to Expand AI-Powered Cancer Drug Prediction
  • Paris-based Orakl Oncology has raised an oversubscribed $34 million Series A, co-led by Norrsken VC and Singular, bringing its total funding to $50 million.

  • Founded in 2023 as a spinout from Gustave Roussy, Orakl grows patient-derived tumor organoids and tests them against drugs, combining experimental results with genomic, transcriptomic, phenotypic and clinical data to build predictive models—its vision is to create “virtual cancer patients” that help assess drugs before clinical trials.

  • Its O-Predict product is designed to forecast trial outcomes, compare candidate treatments and identify response biomarkers, while O-Target focuses on discovering therapeutic targets; these tools support research and drug-development decisions, not individualized treatment recommendations.

  • Pagès said the platform is not ready for patient care, and its predictions should not be treated as clinical advice.

  • An April 2026 preprint describes SCOPE, an early-stage system trained on 54 treatment lines from 52 patients with metastatic colorectal or pancreatic cancer and externally evaluated across 32 treatment arms from 23 trials; it reported an R² of 0.85 for median progression-free survival and 0.71 for objective response rate, with organoid and clinical data performing better together than either alone.

  • SCOPE ranked the better-performing treatment in seven of eight head-to-head comparisons, but the study has not been peer reviewed and its validation set was modest and dominated by chemotherapy, leaving performance on newer drugs uncertain.

  • The study’s trial-level results do not establish accuracy for individual patients or other cancer types; the authors say individual-patient validation is ongoing and independent prospective validation remains necessary.

  • Norrsken says 18 of the 20 largest pharmaceutical companies are in Orakl’s commercial pipeline, though that does not mean they are all signed customers; some initial engagements have developed into multi-year collaborations.

  • The round also included InfraVia, Serena, the Patient Autonome Fund managed by Bpifrance, teampact.ventures and Plug and Play, alongside existing investors Verve Ventures, Speedinvest and HCVC.

  • Orakl will use the funding to expand its data and AI research, increase data production fivefold, add lung and stomach cancers to its work, and build teams in the United States and United Kingdom.

  • The company began with colorectal and pancreatic cancers and is expanding its platform to lung and gastric cancers.

  • Founded by Diane-Laure Pagès, Fanny Jaulin and Gustave Ronteix, Orakl has grown from three founders to more than 40 employees, about 30% of whom hold doctoral degrees.

Summary based on 7 sources


Get a daily email with more Startups stories

Sources

Orakl Oncology raises $34M to predict cancer drug results with AI

TNW | Artificial-intelligence • Nov 12, 2026

Orakl Oncology raises $34M to predict cancer drug results with AI


More Stories